Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells $259,920.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $21.66, for a total transaction of $259,920.00. Following the completion of the transaction, the chief executive officer now directly owns 1,075,525 shares in the company, valued at $23,295,871.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Samuel Kintz also recently made the following trade(s):

• On Tuesday, May 28th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $23.18, for a total transaction of $278,160.00.
• On Thursday, April 25th, Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.89, for a total transaction of $202,680.00.
• On Thursday, April 11th, Samuel Kintz sold 47,709 shares of Enliven Therapeutics stock. The shares were sold at an average price of $25.04, for a total transaction of $1,194,633.36.

Enliven Therapeutics Trading Down 0.3 %

Shares of ELVN stock opened at $23.37 on Friday. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $26.00. The stock has a market cap of $1.10 billion, a PE ratio of -12.11 and a beta of 1.11. The company’s fifty day moving average price is $21.66 and its 200-day moving average price is $17.75.

Enliven Therapeutics (NASDAQ:ELVN) last announced its earnings results on Tuesday, May 14th. The company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.04. On average, sell-side analysts forecast that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on ELVN shares. Mizuho started coverage on shares of Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price target on the stock. Robert W. Baird started coverage on shares of Enliven Therapeutics in a report on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price target on the stock. Finally, Baird R W upgraded shares of Enliven Therapeutics to a “strong-buy” rating in a report on Tuesday, June 11th.

Institutional Trading of Enliven Therapeutics

Hedge funds have recently modified their holdings of the business. AJOVista LLC bought a new position in Enliven Therapeutics in the 4th quarter worth about $28,000. China Universal Asset Management Co. Ltd. bought a new position in Enliven Therapeutics in the 4th quarter worth about $66,000. Exchange Traded Concepts LLC boosted its stake in Enliven Therapeutics by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after purchasing an additional 2,208 shares in the last quarter. EntryPoint Capital LLC bought a new position in Enliven Therapeutics in the 1st quarter worth about $167,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its stake in Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after purchasing an additional 1,029 shares in the last quarter. Institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.